Casperome® Clinical Studies: Quantified Relief Across Joint, Gut & Eye Health

Key Takeaways

• Enhanced bioavailability – Casperome® uses Phytosome® technology to improve boswellic acid absorption and systemic delivery.

• Higher tissue distribution – Studies show significantly increased concentrations in muscle, brain, and eye tissues compared with standard Boswellia extracts.

• Multi-system benefits – Clinical evidence supports joint mobility, gastrointestinal balance, and dry eye relief.

• Full-spectrum boswellic acids – Casperome® preserves the complete triterpenic acid profile, not just isolated compounds.

• Clinically validated formulation – Human pharmacokinetic studies confirm faster absorption and improved plasma exposure.
  
  

Casperome® is a clinically studied, lecithin-based Boswellia serrata formulation designed to enhance boswellic acid (BA) absorption. Unlike conventional extracts, it preserves the full triterpenic acid spectrum while significantly improving systemic and tissue bioavailability.

Clinical studies and preclinical research demonstrate measurable improvements across:

• Joint and musculoskeletal comfort

• Gastrointestinal balance

• Ocular surface and dry eye health
  
  

Its advanced Phytosome® delivery system ensures that Casperome® delivers anti-inflammatory Boswellia effectively, supporting joint mobility and promoting gut mucosal balance, making it a clinically validated choice for whole-body wellness.

Boswellic Acid Content & Comparative Formulation

Casperome™ contains roughly 33% of the BA content of BE in weight-equivalent comparisons but achieves superior plasma and tissue concentrations.

Human Pharmacokinetics (PK) & Preclinical Plasma Findings

Human PK Study (Healthy Subjects)

• Design: Randomized, single-blind, cross-over

• Population: 12 healthy subjects

• Intervention: 500 mg Casperome® (150–165 mg Boswellia extract equivalent) vs 500 mg non-formulated extract

• Wash-out: ≥ 21 days

• Sampling: Up to 72 hours post-dose
  
  

Key Findings:

• Faster Tmax across six boswellic acids

• Up to 3–4× higher AUC for several acids

• Improved plasma consistency
  
  

Rat Plasma AUC_last Ratios (Casperome™ vs BE):

*Statistically significant (p < 0.05)

Casperome™ demonstrates significantly higher systemic exposure compared to standard Boswellia extract, confirming enhanced bioavailability.

Tissue Distribution (8h Post-Dose)

Casperome™ significantly improves tissue penetration, including poorly vascularized organs like the brain and eyes, supporting multi-system anti-inflammatory activity.

Management of Remissive Ulcerative Colitis

Study Population: 43 patients with UC in remission phase
Intervention: Daily Casperome® supplementation (n = 22) vs no supplementation (n = 21) for 4 weeks

Clinical Symptoms (vs. control):

• Intestinal pain: -33%

• Bowel movements: -45%

• Cramps: -41%

• General malaise: -34%

• Diarrhea with blood episodes: -75%

• Rectum involvement: -67%

• Occult blood in stool: -50%
  
  

Biomarkers of Activity:

• Blood loss in stools reduced (+18% plasma hemoglobin)

• Chronic inflammation reduced (-32% WBC count)

• Calprotectin levels improved; patients with <100 μg/ml 26% higher
  
  

Casperome® supplementation attenuates mild UC symptoms in remission, reducing the need for drugs and medical consultations.

Clinical Evidence: Gut & Gastrointestinal Health

• Improvement in abdominal discomfort scores

• Reduced bloating

• Better stool regularity

• Supported in IBS management
  
  

Short-Term IBS (4 weeks):

• Population: 71 subjects

• Casperome® 250 mg/day vs standard antispasmodics
  
  

Long-Term IBS (6 months):

• Population: 69 subjects

• Casperome® 250 mg/day vs standard management
  
  

Long-Term Results vs Standard Management:

• Recurrent abdominal pain: -57%

• Abdominal pain at pressure: -61%

• Altered bowel movements: -54%

• Meteorism: -68%

• Spontaneous cramps: -89%

• Rescue medications: 14% (vs 71% SM)

• Medical consultations/hospital admissions: 14% (vs 26% SM)
  
  

Clinical Evidence: Joint & Neurotendinopathies

• Ache relief: VAS & Neuropathy Total Symptom Score improvement

• Reduced analgesic use: within 7–10 days

• Functional improvement: PRTEE & VIS-A for tendinopathies (2 weeks)

• Life quality improvement: better sleep within 10 days
  
  

Clinical Evidence: Ocular Surface & Dry Eye

• Improved dry eye symptom scores

• Enhanced tear stability

• Reduced ocular discomfort

• Tissue distribution in eyes up to 17× higher than standard extract
  
  

Casperome® vs Standard Boswellia Extract

Mechanistic Rationale: Multi-Target Biological Activity

Boswellic acids interact with:

• Enzymatic mediators in inflammatory pathways

• Immune modulation

• Tissue-specific anti-inflammatory cascades
  
  

Enhanced tissue distribution explains multi-system benefits and the anti-inflammatory Boswellia profile.

Frequently Asked Questions (FAQs)

What makes Casperome® different from standard Boswellia extracts?

Casperome® uses a Phytosome® delivery system that enhances absorption and tissue distribution. Plasma and tissue studies demonstrate significantly higher BA levels compared to conventional extracts.

Does Casperome® contain only AKBA?

No. Casperome® preserves the full BA spectrum, including KBA, AKBA, βBA, αBA, and acetyl derivatives.

Can Casperome® reach tissues effectively, like the brain or eyes?

Yes. Preclinical studies show Casperome® increases brain concentrations of KBA and AKBA by 35× and eye concentrations by up to 17×.

Is Casperome® suitable for long-term supplementation?

Yes. Casperome® is designed to promote joint mobility support and maintain gut mucosal balance.

Take the Next Step Toward Advanced Boswellia Support

Casperome® (Phytosome® Boswellia) offers:

• Enhanced bioavailability & tissue distribution

• Full-spectrum triterpenic profile

• Multi-system support (joints, gut, dry eyes, ulcerative colitis remission, and IBS symptom management)

• Human PK and tissue evidence
  
  

With its anti-inflammatory Boswellia profile, Casperome® is designed to support joint mobility and maintain gut mucosal balance, helping you achieve better overall health.

Discover evidence-based Boswellia solutions to elevate your approach to joint comfort, gut balance, and ocular health today with Just Glow.